Abiopharma

🔍 GRANT HUGH (Director)

Company: LINDE PLC (LIN)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: H | shares_owned_after: 1,081.91
• Acquired 473 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 473.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 79 shares of Deferred Stock Units (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 446.70 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Holds 470 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 470.16 | Footnotes: F1, F3, F3

Footnotes:

• F1: Conversion to Linde plc Ordinary Shares is on a 1-for-1 basis.
• F2: This RSU award shall vest in full one year after the March 9, 2026 date of grant, provided that the awardee serves on the Linde plc Board of Directors continuously through the vesting date, except under certain circumstances in which a pro-rata payout may be made. The payout of the vested RSU award has been deferred and will be made in Ordinary Shares on a one-for-one basis upon the reporting person's termination of service on the Board of Directors.
• F3: Restricted Stock Units that have fully vested but whose payout in Linde plc Ordinary Shares has been deferred by the reporting person until termination of services as a director.
• F4: Deferred stock units acquired under the Linde Non-Employee Director Deferral Plan ("Plan"). The deferred stock units will payout in Linde plc Ordinary Shares on a one-for-one basis in accordance with the Plan.